(Q53647789)

16 May 2018

reason for preferred rank

title

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer (English)

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

3 April 2024

Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624712

3 April 2024

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

3 April 2024

author name string

Jean Latreille

1

1 reference

16 May 2018

Gerald Batist

2

1 reference

16 May 2018

Francis Laberge

3

1 reference

16 May 2018

Pierre Champagne

4

1 reference

16 May 2018

Daniel Croteau

5

1 reference

16 May 2018

Pierre Falardeau

6

1 reference

16 May 2018

Carey Levinton

7

1 reference

16 May 2018

Claude Hariton

8

1 reference

16 May 2018

Eric Dupont

10

1 reference

16 May 2018

William K. Evans

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624712

3 April 2024

language of work or name

English

0 references

publication date

1 January 2003

1 reference

16 May 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S1525730411702856?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

https://api.elsevier.com/content/article/PII:S1525730411702856?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

3 April 2024

1 reference

16 May 2018

volume

4

1 reference

16 May 2018

issue

4

1 reference

16 May 2018

page(s)

231-236

1 reference

16 May 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

cites work

3

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Tumor angiogenesis: therapeutic implications

3 April 2024

4

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Anti-angiogenesis: a multipurpose therapeutic tool?

3 April 2024

6

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue

3 April 2024

13

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer

3 April 2024

15

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis

3 April 2024

16

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

3 April 2024

17

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

3 April 2024

18

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

3 April 2024

19

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

3 April 2024

20

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.003

3 April 2024

Identifiers

1 reference

16 May 2018

1 reference

16 May 2018